BioXcel Therapeutics, Inc. Common Stock (BTAI) Technical Analysis
$0.07
Market is closed - opens 7 PM, 28 Sep 2026
Insights
- BioXcel Therapeutics Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for BioXcel Therapeutics Inc. stock suggests that it is a good time to buy
- Based on analysis of the Moving Averages technical indicator, BioXcel Therapeutics Inc. stock is in a downtrend↘️
- Based on analysis of the Pivot Points, the current market trend for BioXcel Therapeutics Inc. stock suggests that it is a good time to sell or bad time to initiate a fresh position
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 20.14 | Buy |
Stochastic | 0.59, 0.67 | Neutral |
Ultimate Oscillator | 19.11 | Buy |
Stochastic Relative Strength Index | 1.11, 0.74 | Buy |
Moving Average Convergence Divergence | -0.22, -0.15 | Neutral |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 0.38 | Sell |
20 | 0.66 | Sell |
50 | 0.84 | Sell |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 0.33 | Sell |
20 | 0.52 | Sell |
50 | 0.77 | Sell |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 0.14 | Sell |
20 | 0.17 | Sell |
50 | 0.24 | Sell |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 0.07 | Sell |
20 | 0.26 | Sell |
50 | 0.53 | Sell |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | -0.01 | Sell |
20 | 0.11 | Sell |
50 | 0.38 | Sell |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 0.14 |
Resistance L2 | 0.14 |
Resistance L1 | 0.13 |
Pivot Point | 0.12 |
Support L1 | 0.11 |
Support L2 | 0.1 |
Support L3 | 0.09 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.